Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI) -- Ignore unavailable to you. Want to Upgrade?

To: Barron Von Hymen who wrote (266)	2/22/1998 1:39:00 AM
From: George Mc Geary	Read Replies (1) \| Respond to of 1321

Barron, <<But you are right QLT has half the market cap and appears at first glance to be further on track. Also their "cash burn rate" for R&D is much lower, roughly half, but Miravant still has twice as much cash.>> MVRT has 14.1M shares outstanding while QLT has 26.1 shares outstanding. That would also help account the discrepancy in share value. If you run a cash to price you will notice that QLT is 14.875 / 2.32 = 6.411 while MRVT is 36.8125 / 5.54 = 6.645 . If you apply the MRVT ratio to QLT the stock price would be $15.41 . My numbers are from Yahoo Profile so do not know how accurate they are. Don't feel the stock is too overpriced but there was good news coming Friday and someone knew it since the stock price jumped and will most likely go up a little further on Monday. This may be good for QLT shareholders for it brings more attention to QLT for someone who knows a little about this AMD stuff. George